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RESUMO 
 
O cancro da mama é o segundo cancro mais frequente a nível mundial, sendo o 
mais incidente entre as mulheres. Apesar dos importantes avanços terapêuticos, o 
cancro da mama metastático continua a estar associado à maior taxa de mortalidade 
por cancro entre as mulheres.    
O cancro da mama é uma doença bastante heterogénea que engloba vários 
subtipos histológicos e moleculares que influenciam o comportamento, a 
agressividade tumoral, e consequentemente, o prognóstico clínico. A classificação de 
cancro da mama com base na expressão molecular do receptor de estrogénio (RE), do 
receptor de progesterona (RP), do receptor 2 do factor de crescimento (HER2) e do 
índice proliferativo (Ki-67) tem particular interesse clínico e implicações terapêuticas. 
Do ponto de vista clínico, existem três subtipos de cancro da mama com maior 
relevância: o subtipo luminal com dois subgrupos: Luminal A (RE+ e/ou RP+, HER2-, 
Ki67 baixo) e Luminal B (RE+ e/ou RP+, HER2+ ou Ki67 elevado); o subtipo com 
sobreexpressão de HER2 ou HER2+ (RE-, PR-, HER2+); e o subtipo triplo negativo (RE-, 
RP- HER2-). O cancro de mama luminal é o mais comum, correspondendo a cerca de 
60% de todos os casos, sendo também o menos agressivo. Uma vez que é 
caracterizado pela expressão de receptores hormonais e o seu crescimento é 
hormono-dependente, os doentes com cancro da mama luminal beneficiam de 
tratamento com hormono-terapia. As opções terapêuticas são várias e incluem o 
tamoxifeno e o fulvestrant que, por mecanismos diferentes, têm afinidade para o RE, 
impedindo a ligação do estrogénio e levando ao bloqueio da principal via de 
sinalização implicada na proliferação das células tumorais. No entanto, cerca de 30% 
dos casos de cancro de mama luminal torna-se resistente à terapia e os doentes vêm a 
desenvolver cancro metastático. O cancro metastático é a maior causa de morte por 
cancro e é considerado o maior desafio quer para os médicos e doentes, quer para a 
investigação. Assim, é muito importante descobrir novos mecanismos de resistência à 
terapia, bem como biomarcadores de prognóstico e/ou preditivos de resposta às 
diversas opções terapêuticas.  
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A YB-1 é uma proteína multifuncional, que pertence à familia de proteinas Y-
Box Binding Proteins e que está envolvida em vários processos celulares importantes 
para o crescimento e o desenvolvimento celular. Geralmente localizada no citoplasma 
da célula, uma vez activada por fosforilação a YB-1 é translocada para o núcleo onde 
actua como factor de transcrição e promove a expressão de genes associados ao 
crescimento, ao ciclo celular e à quimio-resistência. Vários estudos demonstraram o 
papel oncogénico da YB-1, que foi já associada a todos os hallmarks do cancro. Em 
relação ao cancro da mama, especificamente, a expressão elevada de YB-1 está 
associada ao subtipo molecular triplo negativo e a um pior prognóstico dos doentes.   
Nesta dissertação propusemos estudar a proteína YB-1 em cancro da mama 
luminal. Neste tipo de cancro, foi já demonstrado in vitro que a expressão aumentada 
de YB-1 está associada à perda da expressão de RE e resistência à hormono-terapia, e 
ao aumento da transcrição de HER2. Desta forma, colocámos a hipótese de que a 
expressão elevada de YB-1 em tumores primários de cancro da mama RE+ pode não só 
estar associada a um mau prognóstico, mas também à resistência à hormono-terapia e 
à perda de RE nas metástases. Para abordar esta hipótese, avaliámos 
retrospectivamente a associação entre YB-1 e p-YB-1 e a sobrevida livre de doença e 
sobrevida global, usando uma coorte de 80 tumores primários e 51 metástases 
emparelhadas. Avaliámos ainda uma possível associação com alterações no RE, RP e 
HER2 nas metástases. 
Os níveis de proteína foram detectados por imunohistoquímica e as amostras 
foram avaliadas por dois médicos patologistas independentes. Os resultados mostram 
que níveis elevados de YB-1 ou a localização nuclear de p-YB-1 estão associados à 
ausência de RE (p=0,0383 e p=0,0306, respectivamente). Em relação aos outcomes 
clínicos, a elevada expressão de YB-1 nos tumores, bem como a localização nuclear de 
YB-1 ou p-YB-1, mostraram estar associadas a menor sobrevivência global (p=0,0437; 
p=0,0221 e p=0,0163, respectivamente). Embora não tenha sido clara uma associação 
entre a expressão de YB-1 e as alterações moleculares que se observaram entre os 
tumores primários e as metástases, 45,8% das metástases com status molecular 
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diferente do tumor primário, eram positivas para YB-1 nuclear, em comparação com 
37% sem YB-1 nuclear. 
Globalmente, a nossa análise de amostras de cancro da mama humano 
corrobora a importância da YB-1 como biomarcador de mau prognóstico e mostra que 
esta proteína está implicada na negatividade de RE. Além disso, conseguimos mostrar 
pela primeira vez que a hormono-terapia adjuvante pode estar implicada na seleção de 
clones com expressão elevada de YB-1 e que isto pode estar associado com o pior 
prognóstico de doentes com tumores com elevada expressão de YB-1. 
Assim, também questionámos se a resistência adquirida à hormono-terapia em 
cancro da mama RE+ é acompanhada por uma alteração na expressão de YB-1; e 
sendo assim, se isso afecta a sensibilidade a outras terapias alvo. Para responder a 
essas questões, seleccionámos in vitro linhas celulares com resistência adquirida a 
diferentes terapias e avaliámos: a expressão de YB-1, RE, RP, HER2 e Ciclina D1; e a 
sensibilidade à hormono-terapia, terapia anti-HER2, e inibidores de mTOR e CDK4/6, 
actualmente usados como agentes únicos ou em combinação, para tratar cancro da 
mama luminal. 
Os nossos resultados mostram que a sobreexpressão de YB-1 em células de 
cancro da mama luminal, MCF-7, leva à diminuição da expressão de receptores 
hormonais (RE e RP), e aumenta ligeiramente a expressão de HER2. Em consequência, 
estas células tornam-se menos sensíveis à hormono-terapia (tamoxifeno e fulvestrano) 
e mais sensíveis à terapia anti-HER2 (lapatinib). De seguida, e para testar se a 
expressão de YB-1 estaria associada à resistência adquirida, mantivemos quatro linhas 
celulares de cancro da mama luminal expostas a baixas concentrações de fármacos 
diferentes por um periodo de cinco meses e avaliámos os níveis de expressão de YB-1, 
bem como os níveis de expressão dos receptores hormonais RE, RP e HER2. Os nossos 
resultados mostram que as células MCF-7 resistentes aos fármacos têm uma 
diminuição na expressão dos receptores hormonais e Ciclina D1, embora não tenham 
sido detectadas diferenças nos níveis de expressão de YB-1. Em concordância com 
estes resultados, a linha celular derivada de MCF-7 e resistente ao tamoxifeno 
apresentou uma menor taxa proliferativa e com menor dependência do estradiol, 
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quando comparada com a linha parental não tratada. No entanto, as linhas celulares 
derivadas de T47D resistentes ao tamoxifeno, fulvestrano e lapatinib mostram ter um 
aumento de YBX1, ESR1 e ERBB2, embora nem sempre se traduza num aumento ao 
nível da proteína.   
Adicionalmente, avaliámos a resposta das linhas celulares derivadas de MCF-7 e 
T47D resistentes à hormono-terapia, a três terapias usadas na clínica para cancro da 
mama luminal metastático: lapatinib (anti-HER2), everolimus (inibidor do mTOR) e 
palbociclib (inibidor da CDK4/6). Curiosamente, os clones resistentes à hormono-
terapia não se tornam mais resistentes às terapias alternativas, havendo até uma 
tendência para serem mais sensíveis, em especial a linha MCF-7 resistente ao 
Fulvestrano. 
Em conclusão, os nossos resultados demonstram que a proteína YB-1 está 
associada a um pior prognóstico em cancro da mama e que a sua expressão se 
correlaciona negativamente com os níveis de RE. Assim, esta proteína poderá ser um 
biomarcador de resposta à terapia em cancro da mama luminal, uma vez que a terapia 
standard é direccionada para o RE.  
  
Palavras-chave: Cancro da mama luminal; Y-Box binding protein 1 (YB-1); resistência à 
terapia; Biomarcadores preditivos e/ou prognósticos.  
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ABSTRACT 
 
Breast cancer (BC) is the most common cancer among women worldwide, and 
Luminal BC is the most frequent and less aggressive subtype of BC, that affects about 
60% of BC new cases. Luminal BC is characterized by the expression of hormone 
receptors, estrogen receptor (ER) and/or progesterone receptor (PR), and it could be 
divided in two subgroups depending of HER2 overexpression. Therefore, Luminal BC 
benefits from hormone-therapy (HT), as tamoxifen and fulvestrant, that blocks the ER-
pathway and control the cell growth and development. However, there is a percentage 
of tumours that became resistant to therapy and develop metastases. Metastatic BC is 
the biggest challenge, and the major responsible for BC-related deaths.  
 YB-1 is a multifunctional protein that is involved in a variety of cellular 
processes related with growth and development. Normally, it is localized on cytoplasm 
and upon activation by phosphorylation, YB-1 translocates to the nucleus. As a 
transcription factor, YB-1 promotes the transcription of genes related with cell cycle, 
growth and drug resistance. Therefore, YB-1 has been associated with all hallmarks of 
cancer in diverse types of cancers, including BC. In this project we aimed to associate 
YB-1 with prognosis and resistance to HT in luminal BC, using a clinical and in vitro 
approach. Overall, our analysis in a cohort of 80 primary BC tumours and 51 paired 
metastases corroborates the importance of YB-1 as a biomarker of poor prognosis and 
shows that it is associated with ER negativity. Moreover, we provide the first data that 
shows that adjuvant HT may be implicated in the selection of clones with elevated YB-
1 expression, which may be associated with the poor outcome of YB-1High patients.   
Our in vitro results show that YB-1 overexpression decreases the expression of 
hormone receptors, and that cells become more resistant to HT and more sensitive to 
lapatinib (anti-HER2 therapy). Moreover, cells with acquired resistance to tamoxifen, 
fulvestrant or lapatinib show some alterations in gene transcription, but HT-resistant 
cells remain sensitive to alternative therapeutics such as lapatinib, everolimus or 
palbociclib. 
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All things considered, our results suggest that YB-1 could be a predictive 
biomarker of HT-resistance and tumour aggressiveness, and that it deserves further 
studies. 
 
Keywords: Luminal Breast Cancer; Y-Box Binding Protein 1 (YB-1); Therapeutic 
Resistance; Prognostic Biomarker 
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1. INTRODUCTION 
 
1.1. Breast Cancer Epidemiology 
 
Breast Cancer (BC) is the second most commonly diagnosed cancer worldwide. 
According to the International Agency for Research on Cancer (IARC), BC accounts for 
about 12% of all new cancer cases, closely after lung cancer. In women, BC is by far the 
most common cancer and the leading cause of cancer death worldwide. IACR 
estimates that in 2018, BC will correspond to 25% of all new cancer cases (2,15 million 
new BC cases), causing 15% of all cancer-related deaths (630,000 deaths from BC).1 
These numbers reflect that despite great advances in BC early detection and 
treatment, BC incidence and mortality is still very high.  
In Portugal, although the incidence of BC is lower than in the rest of Europe, it 
is still the most frequent female cancer. The World Health Organization (WHO) data 
shows that in 2018 there were 6,974 women diagnosed with BC in Portugal and 1,748 
deaths, corresponding to 12% of all cancer deaths. (GLOBOCAN 2018, 
https://www.uicc.org/new-global-cancer-data-globocan-2018; accessed in November 
2018) 
 
1.2. Breast Cancer Molecular Subtypes 
 
BC is a heterogeneous disease, comprising different histological and molecular 
subtypes and treatment sensitivity profiles. Therefore, prognosis is also heterogeneous 
and depends on the tumour characteristics.2 
 BC is classified based on histological evidences, the molecular status of 
estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 
receptor 2 (HER2) and Ki-67 expression. There are three major subtypes of BC with 
clinical interest.2,3 Luminal BC, including Luminal A (ER+ and/or PR+, HER2-, low Ki67) 
and Luminal B (ER+ and/or PR+, HER2+ or high Ki67); HER2 amplified BC (ER-, PR-, 
HER2+); and Triple Negative BC (TNBC; ER-, PR-, HER2-). Luminal BC is the most 
common (60% of all cases) and less aggressive type of BC, while TNBC is associated 
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with worst prognosis.4,5 The molecular status of a tumour is extremely relevant for 
clinical management, since the presence of ER, PR and HER2 predict response to 
targeted-therapies. 
 
1.2.1. Luminal BC and ER signaling 
Luminal BC is characterized by the expression of Hormone Receptors, mainly 
ER, and its growth is dependent of an ER-pathway, which is constitutively activated.6 
Hormone therapy is the first line therapeutic option for Luminal BC and shows higher 
efficacy for tumours with elevated levels of ER expression.7 Although tumour growth is 
more indolent in Luminal BC (especially in Luminal A BC), and these tumours are 
associated with good response rates, resistance to therapy often occurs, and 
approximately 30% of patients will relapse.4 Among ER+ BC, the overexpression of 
HER2 (HER2+) can also influence the prognosis and response to therapy, and 
ER+/HER2+ BC has been shown to be associated with higher relapse rates when 
compared with ER+/HER2- BC.3     
 ERs are cytoplasmic receptors which, upon activation by estrogen (17β-
estradiol), are translocated to the nucleus and act as transcription factors.8,9 ER 
downstream genes mostly include genes involved in the proliferation and 
differentiation.  
There are two ERs, namely ERα and ERβ, encoded by ESR1 and ESR2 genes, 
respectively.6 Both ERα and ERβ have a major affinity for estrogen. Despite having 
independent transcription activity as homodimers, they can also bind to each other 
and act as a heterodimer.9 Both ERs are expressed in hormone-dependent cells, 
however ERα is mostly related with the growth of mammary epithelial cells, while ERβ 
has a major effect in the differentiation of the mammary gland.10,11 In ER+ BC is ERα 
which is overexpressed, increasing the tumour growth, and is considered an oncogenic 
marker.12 On the contrary, ERβ expression is normally downregulated in tumour 
tissues and there are no clear evidences of positive effects by targeting this protein.10 
The impact of ERβ in estrogen-dependent cancer cells is still unclear, but it has been 
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suggested that it could act as an inhibitory modulator of ERα activity.13 From herein, 
ER+ BC will mean BC expressing ERα. 
1.2.1.1. Hormone therapy and acquired resistance 
The current standard of care treatments for BC include not only surgery, 
radiotherapy and chemotherapy, but also, targeted therapies like hormone therapy 
(HT) and a wide variety of biological therapies. Therapeutic regimens often include a 
combination of different therapies, depending on staging and tumour characteristics, 
including the molecular status.14  
In the case of Luminal BC there is benefit from the use of HT, which includes 
aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and 
selective estrogen downregulators (SERDs). AIs, like anastrozole or letrozole, block the 
enzymatic activity of aromatase, decreasing the production of estrogen in the adipose 
tissue.15 Since AIs do not inhibit the synthesis of ovarian estrogen, they are used to 
treat postmenopausal women. In the premenopausal setting, SERMs or SERDs are 
used to block the binding of estrogen to ER. SERMs, like tamoxifen, bind to ER and 
impair estrogen binding to the receptor, decreasing its activity in gene transcription.16 
SERDs, like fulvestrant, also have a high affinity to ER, but additionally induce ER 
degradation.17 In both cases, the ER-pathway is inhibited, decreasing proliferation and 
inducing apoptosis.9 
However, tumours often manage to escape therapy, either adjuvant leading to 
relapse, or metastatic leading to progression and death. Advanced (or metastatic) 
cancer correspond to tumour cells which were able to leave the primary tumour, 
spread into distant organs and grow from micro to macro metastases, and represents 
one of the biggest challenges for clinicians and researchers. As mentioned before, 
nearly 30% of ER+ BC patients will relapse on the course of their disease, mainly in 
bone, but also in lung, liver and brain. Relapse may occur within months or even years 
after diagnosis of primary tumour.  
Known mechanisms of resistance to HT include the loss of ER accompanied by 
the upregulation of Epidermal Growth Factor Receptor (EGFR)18, Insulin-like Growth 
Factor (IGF)19 and HER220 proteins, or downstream activation of Phosphoinositide 3-
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Kinase (PI3K) - Serine/threonine Kinase (AKT) - Mammalian Target of Rapamycin 
(mTOR) pathway.21 Therefore, inhibitors of mTOR, like everolimus, have been used to 
control the proliferation, cell growth and tumour progression. Combining everolimus 
with HT has demonstrated benefit for metastatic BC patients, blocking the alternative 
pathway and restoring the sensitivity to HT.22,23 
In the case of metastatic Luminal BC with HER2 amplification, some studies 
have shown that the combination of an AI, like letrozole or anastrozole, with anti-HER2 
therapy, like lapatinib, versus AI alone is beneficial.24.25 Moreover, also in ER+/HER2- 
tumours, the combination of an AI with anti-HER2 therapy has shown to be beneficial, 
since upregulation of HER2 has been described as one of the resistance mechanism 
adopted by tumour cells in response to AIs.26 Additionally, the anti-HER2 trastuzumab 
has shown to reverse the resistance to AIs, upon HER2 increase and ER decrease in 
ER+/HER2- cells and xenografts.27  
Likewise, the expression of cyclins are also frequently altered in cancer, 
particularly the cyclin A, B and D upregulation are observed in relapsed BC.28,29 Cyclins 
are regulators of cell cycle progression, activated upon binding to cyclin-dependent 
serine/threonine protein kinases (CDKs), whose expression is dependent on cell cycle 
phase. CDK4 and CDK6 bind to D-type cyclins, and cyclin D/CDK4/6 complexes mediate 
the transition between G0/G1 and S phase of the cell cycle.30 Moreover, cyclin D1 
overexpression, downstream of ERα, is associated with higher proliferative rate and a 
stem cell phenotype.31 In this context, cell cycle inhibitors or downregulators have 
been studied in order to control the cell cycle and growth responsible for tumour 
resistance. Currently, there are three cyclin-dependent kinase 4/6 (CDK4/6) inhibitors: 
ribociclib, palbociclib and abemaciclib, which have emerged as a substantial advance 
for patients with ER+/HER2- BC.32 A randomised phase II trial of the CDK4/6 inhibitor 
palbociclib plus letrozole versus letrozole, and a phase III of palbociclib plus fulvestrant 
versus fulvestrant, showed significantly increased progression-free survival (PFS) when 
compared with HT alone in first-line and second-line treatment for advanced 
ER+/HER2- BC.33  
 Still, multiple and sequential resistance mechanisms are life-threatening, as 
patients often progress after first and subsequent lines of treatment. Therefore, it is 
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extremely important to identify new mechanisms of resistance as well as predictive 
biomarkers. In the scope of this project we focused on the prognostic and predictive 
value of Y-Box binding protein 1 (YB-1). 
 
1.3. Y-Box Binding Protein 1  
 
YB-1 is a multifunctional protein, encoded by YBX1 gene, that belongs to a large 
family of DNA/RNA-binding proteins, which have an evolutionary ancient cold shock 
domain (CSD). Since YB-1 is involved in several cellular processes like proliferation, 
development and differentiation, this protein is ubiquitously expressed in somatic 
cells, predominantly in early-stages of development.34 
YB-1 has 324 aminoacids and a molecular weight of 36KDa. Its structure 
contains three major domains: The N-terminal domain, rich in alanine and proline 
residues; the CSD, with a phosphorylation site at Serine 102; and a C-terminal domain 
(CTD), which has a nuclear localization signal (NLS), a cleavage site and a cytoplasmic 
retention site (CRS) (Figure 1).  Therefore, YB-1 is able to bind to other proteins and 
nucleic acids.34,35 
 
 
Figure 1. Representative scheme of YB-1 protein structure. YB-1 protein has three major domains: 
(A/P) N-Terminal Domain rich in alanine and proline residues; (CSD) Cold-shock domain that includes a 
phosphorylation site at Serine 102; (CTD) C-Terminal Domain that includes the nuclear localization site 
(NLS), cleavage site (a.a. 219) and cytoplasmic retention site (CRS). Adapted from 34. 
  
Inside the cell, YB-1 can be found both in the cytoplasm and nucleus. 
Unphosphorylated YB-1 is maintained on the cytoplasm, where it plays a key role in 
balancing mRNA translation and stability in a dose-dependent manner, since at a low 
cytoplasmic YB-1/mRNA ratio the translation of mRNA and protein synthesis are 
activated.35 There is also a nucleocytoplasmic shuttling of YB-1 bound to transcribed 
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mRNAs, regulating translation at the cytoplasm. Phosphorylation of cytoplasmic YB-1 
leads to its translocation to the nucleus, where it binds to DNA and regulates 
transcription. 
Although YB-1 has an ancient CSD and was first characterized as binding to the  
Y-box domain on genes’ promoters34, it is now known that it recognizes and bind to 
other motifs in DNA. Some studies have shown that YB-1 has higher affinity to the 
single stranded motifs GGGG, CACC and CATC than to the Y-box domain. Upon binding 
to DNA YB-1 recruits other proteins forming a transcription regulatory complex.34  
YB-1 regulates transcription of several genes related with cell cycle, growth, 
drug resistance and stress response, acting as an activator or repressor. For example, 
nuclear YB-1 positively regulates the transcription of EGFR, ERBB2, MDR1, PI3KCA, 
CCNA2 and CCNB1.5,36 On the other hand, YB-1 inhibits the transcription of ACTB, 
MHCI, MHCII, p53 and VEGF. Moreover, it has been shown that YB-1 is able to 
negatively regulate its own transcription. The promotor region of YBX1 has a 
regulatory sequence which is recognized by Poly-A Binding Protein (PABP). However, 
YB-1 can also bind to this regulatory sequence, impairing the PABP’s affinity and 
supressing its own mRNA translation.37,38,39 
Additionally, YB-1 can be secreted by a non-canonical secretion mechanism34. It 
has been reported that secreted YB-1 (sYB-1) may participate on cell-cell signalling, 
normally in stress and inflammatory conditions, inducing cell cycle arrest.40 
Interestingly, sYB-1 is found in patients’ serum from different tumours and different 
grades of malignancies, including BC.41 In our previous work we have found an 
association between sYB-1 and the presence of extra-bone metastases and faster bone 
disease progression, in patients with BC and bone metastases.42 Therefore, we 
hypothesize that the detection of sYB-1 in patients with BC and bone metastases may 
indicate a higher tumour burden, in bone and extra-bone locations, and is a biomarker 
of faster bone disease progression. Further studies will clarify the importance and role 
of sYB-1 in the cancer setting but the presence of sYB-1 in serum can be an important 
biomarker.  
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1.3.1. YB-1 as an Oncoprotein 
Since YB-1 plays a key role in development and survival, the impact of YB-1 in 
oncogenesis has been the subject of several studies. Due to YB-1’s role as transcription 
factor and its ability of binding to several proteins, it is not a surprise that YB-1 may 
affect and deregulate oncogenic signalling pathways. In fact, YB-1 has been shown to 
be correlated with all hallmarks of cancer, and an elevated YB-1 expression is 
associated with poor prognosis in a variety of human cancers including breast43, 
prostate44, non-small cell lung cancer45,50, melanoma46,47, osteosarcoma48 and liver and 
gastric cancer.49 
Increased YB-1 expression has been associated high proliferative rates in 
ovarian cancer and BC, by being a positive regulator of the PI3K/AKT pathway.50,51 It 
was also shown that in melanoma cells MAPKs (PI3K/AKT) promote YB-1 
phosphorylation, inducing its translocation to the nucleus, while NFkB pathway inhibits 
YB-1 activity. NFkB recognizes YB-1 and prevents its phosphorylation and translocation, 
mediating its expression and cell survival.47 Furthermore, an association between YB-1 
and cell cycle proteins also justifies the modulation of proliferation and apoptosis 
rates.28 It has been shown that nuclear YB-1 accumulates during the transition from G1 
to S phase of the cell cycle36, activating CCNA2, CCNB1 and CCND136,48,52, crucial for cell 
cycle progression. Moreover, it has been reported that in HER2-amplified tumours, YB-
1 inhibits apoptosis of tumour cells46, which may occur via mTOR/STAT3 pathway.53,54 
Besides the effect of YB-1 on proliferation and apoptosis, which contributes to 
tumour aggressiveness, YB-1 was also identified as a driver for epithelial-to-
mesenchymal transition (EMT) and drug resistance in many cancers such as BC55,56, 
prostate cancer44, and gastric cancer49, through regulation of the transcription of EMT-
associated genes, like the downregulation of E-cadherin, and up-regulation of Snail, 
Slug and Vimentin.44,49,56  
Increased nuclear YB-1 has been reported as a key factor for drug resistance, by 
inducing the expression of MDR-15,57, and for invasiveness and metastases in BC.58 
Besides that, there is a strong association between YB-1 expression and cell growth in 
BC; and previous studies showed that differential proliferation rates are accompanied 
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by an increase of EGFR, HER2, p-ERK and c-Myc but a decrease of ERα, affecting the 
response to therapies.59  
Thus, BC overexpressing YB-1 may have a higher capacity to develop and 
progress quickly, and in fact, the elevated expression of YB-1 in BC has been associated 
with highly aggressive phenotypes and decreased OS.60 Also, it has been shown that 
YB-1 is more frequently elevated in basal-like tumours and HER2-amplified 
tumours.59,61,62 Concordantly, it was reported a negative association between YB-1 
levels and ER and PR expression, and positive association with HER2 in BC cells.63 
All facts considered, when overexpressed, YB-1 modulates a variety of genes 
which are crucial to cancer development and aggressiveness, and YB-1 can be an 
important biomarker of poor prognosis in BC. 
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2. AIMS 
 
As mentioned before, it was previously shown in vitro and in BC xenografts that 
YB-1 overexpression was responsible for ER down-regulation and HER2 up-regulation, 
contributing to anti-estrogen bypass and resistance to HT in BC cells. Therefore, we 
hypothesized that elevated YB-1 expression in primary ER+ breast tumours may not 
only be associated with poor prognosis but also with the loss of ER in metastases. To 
address this hypothesis, we retrospectively assessed the association between YB-1 and 
p-YB-1 and relapse-free survival (RFS) and overall survival (OS), using a cohort of 
primary tumours and paired metastasis; and evaluated a possible association with 
alterations in ER, PR and HER2 status in primary tumours and paired metastases. 
Moreover, we also interrogated if the acquired resistance to HT in ER+/HER2- 
or HER2+ BC is related to YB-1 expression levels or accompanied by an alteration in YB-
1 expression; and being so, if this affects the sensitivity to other targeted therapies. To 
address these questions, we selected in vitro cells with acquired resistance to different 
therapies, like HT, and evaluated: the expression of YB-1, ER, PR, HER2 and Cyclin D1; 
and the sensitivity to HT, anti-HER2 therapy, and mTOR and CDK4/6 inhibitors, 
currently used as single agents or in combination, to treat Luminal BC. 
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3. MATERIALS AND METHODS 
 
3.1. Human Samples 
3.1.1. Immunohistochemistry 
Expression of YB-1 and p-YB-1 was evaluated by immunohistochemistry (IHC) in 
a retrospective cohort of 131 formalin-fixed paraffin-embedded (FFPE) samples from 
80 human primary breast tumours and 51 paired metastases. In addition to a first sub-
group of 94 samples previously evaluated64, 36 new samples were provided by the 
Pathology Department from CUF Hospital, and all patients signed an Institutional 
informed consent.  
IHC was performed as previously described.64 Briefly, deparaffination and 
antigen retrieval were performed using the PT Link Pre-Treatment Module for Tissue 
Specimes (Dako), according to manufacturer’s instructions, and 5µm tissue sections. 
Next, samples were incubated for 10 min at room temperature (RT) with Peroxidase 
Blocking Solution (Dako) to inhibit endogenous peroxidase activity, followed by an 
incubation with Protein Block Solution (Dako) for 20min at RT, and incubation with 
primary antibodies overnight at 4°C. Primary antibodies included: rabbit anti-human 
YB-1 (1:50, D299, Cell Signaling) and rabbit anti-human p-YB-1 (Ser102) (1:500, Cell 
Signaling); both diluted in Antibody Diluent (Dako). The visualization system Dako REAL 
EnVision Detection System, peroxidase/DAB+, rabbit/mouse (Dako) was used 
according to manufacturer’s instructions, with 2 min of incubation with DAB. Slides 
were counterstained with hematoxylin, dehydrated, mounted with Quick-D mounting 
medium (Klinipath) and visualized in a bright field microscope (Leica DM2500).  
Samples were blinded scored by two Medical Pathologists, and staining 
intensity was classified from 0 to 3: (0) absence of staining, (1) weak, (2) moderated 
and (3) strong staining. H-Score, which ranged from 0 to 300, was calculated based on 
the percentage of cells per intensity. Nuclear localization of YB-1 and p-YB-1 was 
classified as positive or negative.  
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For outcome analysis, the samples were dichotomized according to: 1) low or 
high expression of YB-1 or p-YB-1 using cut-off finder software and OS as endpoint; 2) 
positive or negative nuclear staining. 
3.1.2. Statistical Analysis 
Statistical analyses were performed using GraphPad Prism Software, version 7.0 
(GraphPad Software, www.graphpad.com). For univariate analysis, RFS and OS were 
estimated using Kaplan-Meier curves and differences were determined using the log-
rank test. Survival time was censored at death if patients were still alive at the last 
follow-up. Patients with missing data were excluded from the respective analysis. Two-
tailed unpaired t-test, Fisher’s exact test and Chi-squared test were used to determine 
the association between YB-1 or p-YB-1 expression and clinicopathological 
characteristics of patients. Unpaired t-test was used to determine the concordance 
between YB-1 and p-YB-1 expression in primary tumour and paired metastasis.  
Significance was defined by a p-value<0,05. 
 
3.2. Cell Culture and Cellular Assays 
 
3.2.1. Cell Lines 
Human BC cell lines MDA-MB-231, MCF-7, and MDA-MB-361 were obtained 
from ATCC. T47D and BT474 BC cell lines were kindly provided by Dr. Phillippe 
Clézardin (INSERM). Cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco) containing 1% (v/v) Penicillin/Streptomycin (Pen/Strep, 10,000 U/mL 
Penicillin, 10,000 μg/mL Streptomycin, Gibco), and 10% (v/v) foetal bovine serum (FBS, 
Gibco), except for MDA-MB-361, where 20% (v/v) FBS was used. For MCF-7, T47D and 
BT474 the medium was supplemented with 0,01mg/mL Insulin (Gibco). Medium was 
replaced twice a week and cells were incubated at 37⁰C with 5% CO2 in a humidified 
atmosphere. 
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3.2.2. YB-1 Overexpression 
MCF-7YB-1 OE cell line was derived from MCF-7 cell line by transduction with YB-1 
lentiviral activation particles (Santa Cruz). 4x104 cells were plated in 24-well plates, in 1 
mL of complete medium, and 24 hours later, the medium was replaced by fresh 
medium containing 8µg/mL polybrene, and 30µl of lentiviral particles were added to 
each well. Cells were incubated for 24h and then, the medium was replaced by fresh 
complete culture medium. On the fifth day, infected cells were selected with an 
antibiotic cocktail containing 0,5µg/mL Puromycin, 5µg/mL Blasticidin and 200 μg/mL 
Hygromycin.  
 
3.2.3. Cell Viability Assay  
Cell viability was quantified using the Alamar Blue Assay. 1x104 cells per well 
were seeded in 96-well plates and incubated for 6 days in the presence of specific 
drugs. The medium was replaced every 2 days. For drug sensitivity assays, 1:10 (v/v) 
Alamar blue (Invitrogen) was added after seven days of drug exposure, and after 2h, 
the fluorescence was quantified (560nm excitation/590nm emission) on Microplate 
Reader TECAN Infinite M200. For proliferation assays, Alamar blue was added 24h 
after cell seeding, and fluorescence was measured daily. Each experiment was 
performed in triplicate, with four replicates per condition per experiment.  
 
3.2.4. Selection of drug-resistant cell lines 
To induce drug-resistance, cells were seeded in T25cm2 flasks and incubated for 
5 months in the presence of specific drug: 10nM Tamoxifen (Sigma-Aldrich); 10nM 
Fulvestrant (Sigma); 100nM Lapatinib (Stemcell); 100nM Everolimus (Stemcell); 10nM 
Palbociclib (Sigma). Medium was replaced twice a week. The sensitivity profile was 
assessed after 3 and 5 months of exposure using Alamar Blue Assay as described 
above.  
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3.2.5. E-Screen Assay  
Sensitivity to estradiol was quantified using the E-Screen assay.66 Briefly, cells 
were plated into 24-well plates, at a density of 2x104 cells/mL and incubated for 24h 
hours in standard complete medium. The medium was replaced with phenol-red 
DMEM (Gibco) with 5% csFBS (Gibco) and 1% pen/strep, and cells were incubated in 
the absence or presence of 1nM or 10nM 17β-Estradiol (E2, Sigma-Aldrich). After five 
days, cell viability was quantified using the Alamar Blue Assay as described above, and 
the percentage of viable cells was normalized for control cells growing in a standard 
complete medium. This experiment was performed once with four replicates per 
condition. 
 
 
3.3. RNA isolation, cDNA synthesis and RT-qPCR  
Total RNA was extracted from under confluent cells growing in T25cm2 flasks, 
with the NZY Total RNA Isolation kit (NZYTech), according to the manufacturer’s 
instructions, and was quantified in a NanoDrop 2000 Spectrophotometer (Thermo 
Scientific).  
Complementary DNA (cDNA) was synthesized from 1μg of total RNA, using 
Oligo(dT)18 primer and the NZY M-MuLV First-Strand cDNA Synthesis Kit (NZYTech), 
according to manufacturer’s instructions. 
Interest genes were amplified by semi-quantitative real time PCR (qPCR) in a 
ViiA7 Real-Time PCR System (Applied Biosystems), using 5% cDNA and: TaqMan Gene 
Expression Assays (Table 1) and the 2x TaqMan Gene Expression Master Mix (Applied 
Biosystems); or 10μM of specific primers (Table 2; Invitrogen) and 2x Universal SYBR 
Green Supermix (Biorad). Target gene expression was normalized against the 
housekeeping genes GAPDH or 18S, and the data was analysed using the 2-ΔΔCt method.   
RT-qPCR reactions were performed in triplicate and repeated for three different cDNAs 
synthesized from the same RNA sample.        
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Table 1. TaqMan Gene Expression Assays used in qPCR. 
 Reference 
YBX1 
ESR1 
ERBB2 
PGR 
GAPDH 
 
Hs00358903_g1 
Hs0017486_m1 
Hs01001580_m1 
Hs01556702_m1 
Hs02758991_g1 
 
Table 2. Specific primers used in qPCR. 
 Forward Sequence (5’-3’) Reverse Sequence (5’-3’) 
18S GCCCTATCAACTTTCGATGGTAGT CCGGAATCGAACCCTGATT 
CCND1 ATGTCGTGGCCTCTAAGATGA CAGGTTCCACTTGAGTTC 
       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
3.4. Western blotting 
 Proteins were extracted from under confluent cells growing in T25cm2 flasks. 
Cells were trypsinized and harvested by centrifugation at 450g and 4⁰C for 5 min. Cell 
pellets were lysed in 100μl of RIPA buffer (SIGMA), incubated for 10 min on ice, and 
centrifuged at 16,000g and 4⁰C for 10 min. The supernatants were collected, and 
proteins quantified using Bradford Reagent (VWR Life Science) according to 
manufacturer’s instructions. Protein extracts were diluted in 2X Sample Loading Buffer 
(NZYTech) with 1:100 protease inhibitors cocktail (Cell Signaling), denatured for 10 min 
at 95⁰C and stored at -20⁰C. 
Equal amounts of protein (5μg per lane) were separated by SDS-PAGE and 
transferred onto nitrocellulose membranes (Thermo Fisher Scientific), using an iBlot 2 
system (Invitrogen) according to manufacturer’s instructions.  
Membranes were incubated for 1h in 5% BSA (Santa Cruz) or 5% non-fat milk in 
PBS-T (1X PBS with 0,05% Tween, Sigma-Aldrich), and then, incubated with the primary 
antibodies. Membranes were washed with PBS-T (3X 10 min) and incubated 1h with 
secondary antibodies conjugated with horse radish peroxidase (HRP). Antibodies used, 
and incubation details are listed in Table 3. The washing step was repeated with PBS-T 
(3X 10 min) and proteins were detected using the HRP chemiluminescent substrate 
reagent kit (Invitrogen) on Amersham Imager 680 equipment, according to 
manufacturer’s instructions.  
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Table 3. Antibodies used in Western blotting 
Primary Antibody: Dilution Diluent Incubation 
period, 
Incubation 
temperature 
Rabbit anti-human YB-1 (D299, Cell Signaling) 1:1000  
5%BSA in 
PBS-T 
 
Overnight, 
4⁰C 
 
Rabbit anti-human p-YB-1 (Ser102) (Cell Signaling) 1:500 
Rabbit anti-human ER (Cell Signaling) 1:1000 
Rabbit anti-human HER2 (Cell Signaling) 1:1000 
Rabbit anti-human CyclinD1 (Cell Signaling) 1: 1000 
Mouse-anti-human β-Actin (Cell Signaling) 1: 25000 5% non-fat 
milk in PBS-T 
2 hours,  
RT 
Secondary Antibody:    
Goat anti-rabbit IgG (HRP Conjugate) (Bio Rad) 
1:5000 
5% non-fat 
milk in PBS-T 
1 hour, 
RT Goat anti-mouse IgG (HRP Conjugate) (Bio Rad) 
 
 
3.5. Statistical Analysis 
Statistical analysis and graphs were performed using GraphPad Prism Software, 
version 7.0 (GraphPad Software, www.graphpad.com) and error bars represent the 
standard error of the means (SEM). One-way ANOVA or unpaired t-test were used as 
appropriate. The levels of statistical significance were set at *p<0,05 **p<0,01 and 
***p<0,001.  
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4. RESULTS  
 
4.1. Prognostic value of YB-1 and p-YB-1 expression in primary BC 
The exact applicability of YB-1 as a biomarker in BC is still unclear, but different 
studies have shown an association between elevated YB-1 expression in primary breast 
tumours and poor prognosis, as well as with ER/PR negativity. Moreover, to our 
knowledge, despite the importance of YB-1 phosphorylation in several cellular 
processes, the association between p-YB-1 and clinicopathologic characteristics was 
not addressed so far. Therefore, we proposed to determine the association between 
YB-1 and p-YB-1 expression and cellular localization in primary and metastatic breast 
tumours and clinicopathologic characteristics. For that purpose, we conducted a 
retrospective study, in a cohort of 80 primary BC tissue specimens. The 
clinicopathological characteristics of this cohort are presented in Supplementary Table 
1. The median OS and RFS in this cohort was 4,93 and 2,74 years, respectively.  
The expression of YB-1 and p-YB-1 was assessed by IHC in all 80 primary BC 
tissue specimens, and independently evaluated by two medical pathologists. The 
staining intensity was scored between 0 and 3, being (0) negative, (1) weak, (2) 
moderated and (3) strong staining (Figure 2.A). Two samples were considered not 
evaluable and excluded from further YB-1 analysis. Next, H-Score was calculated based 
on the percentage of cells per staining intensity and the samples were dichotomized 
between high or low YB-1 and p-YB-1 expression (Figure 2.B), using cut-off finder 
software and OS as endpoint, to determine the more significant cut-off. The cut-off 
values are shown in Table 4. In this study, 25,6% (20/78) of patients were classified as 
YB-1 high and 13,8% (11/80) as p-YB-1 high.  
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Figure 2. Representative images of YB-1 and p-YB-1 immunostaining in primary BC tissues. (A) The 
protein expression was scored into four levels of intensity (0-3); (B) Examples of low and high H-Score 
upon dichotomization; and (C) Examples of negative or positive nuclear staining. 
 
Table 4. Cut-off values used for patients’ dichotomization according to low or high YB-1 or p-YB-1 
expression. P-value was calculated using log-rank test. HR – Hazard Ratio; CI – Confidence Interval. 
.  
 
 
 
 
Next, we analysed the association between YB-1 and p-YB-1 expression and 
clinical and pathological characteristics, namely: age at diagnosis, menopausal status, 
TNM stage, tumour grade, tumour size (T), positive lymph nodes (N), receptors’ 
molecular status (positive or negative HER2, ER and PR), and metastasis site (Table 5). 
YB-1 expression was negatively associated with ER status (p=0,0383). We also 
observed a trend for visceral-only relapse in patients with low YB-1 (p=0,0555). 
 YB-1 p-YB-1 
 
Cut off value 285 190 
HR (95%CI) 1,56 (0,95-2,57) 0,32 (0,12-0,88) 
P-value 0,074 0,02 
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Table 5. Association between YB-1 and p-YB-1 expression in primary breast tumours and 
clinicopathologic characteristics. 
 
#Fisher’s exact test; $Chi-Square test 
 
Characteristics YB-1 P  p-YB-1 p 
 Low High  Low High  
Nº of Patients 58 20  69 11  
Age at diagnosis (years)  
  Median 
(range) 
53 
(24 – 83) 
50 
(29 – 77) 
 
 
54 
(24 - 83) 
50 
(39 – 82) 
 
 
Menopausal Status (n, %)  
 Premenopausal 18(31,0) 9 (45,0)  
0,4201# 
24 (34,8) 5 (45,5)  
0,7405#  Postmenopausal 36 (62,1) 10 (50,0) 40(58,0) 6 (54,5) 
 Unknown 4 (6,9) 1 (5,0) 5 (7,2) 0 (-) 
TNM Stage  
 I 5 (8,6) 0 (-)  
 
0,7217# 
5 (7,3) 0 (-)  
 
0,0938# 
 II 15 (25,9) 4 (20,0) 18 (26,1) 1 (9,1) 
 III 15 (25,9) 6 (30,0) 21 (30,4) 1 (9,1) 
 IV 11 (18,9) 2 (10,0) 11 (15,9) 3 (27,3) 
 Unknown 12 (20,7) 8 (40,0) 14 (20,3) 6 (54,5) 
T  
 1 18 (31,0) 4 (20,0)  
 
0,2548$ 
21 (30,4) 1 (9,0)  
 
0,6675$ 
 2 18 (31,0) 8 (40,0) 22 (31,9) 5 (45,5) 
 3 2 (3,5) 2 (10,0) 4 (5,8) 0 (-) 
 4 6 (10,4) 3 (15,0) 9 (13,0) 0 (-) 
 Unknwon 14 (24,1) 3 (15,0) 13 (18,9) 5 (45,5) 
N   
 0 15 (25,9) 5 (25,0)  
 
0,9136$ 
16 (23,2) 4 (36,3)  
 
0,1238$ 
 1 8 (13,8) 5 (25,0) 12(17,4) 1 (9,1) 
 2 6 (10,3) 2 (10,0) 8 (11,6) 1 (9,1) 
 3 7 (12,1) 3 (10,0) 10 (14,5) 0 (-) 
 Unknown 22 (37,9) 5 (25,0) 23 (33,3) 5 (45,5) 
Tumor Grade  
 1 1 (1,7) 0 (-)  
0,9317$ 
1 (1,4) 0 (-)  
0,9185$  2 27 (46,6) 10 (50,0) 32 (46,4) 6 (54,6) 
 3 19 (32,8) 6 (30,0) 22 (31,9) 4 (36,3) 
 Unknown 11 (18,9) 4(20,0) 14 (20,3) 1 (9,1) 
HER2  
 Negative 33 (56,9) 11 (55,0)  
0,9999# 
 
40 (58,0) 5 (45,5)  
0,9999# 
 
 Positive 18 (31,0) 6 (30,0) 22(31,9) 2 (18,2) 
 Unknown 7 (12,1) 3 (15,0) 7 (10,1) 4 (36,3) 
ER  
 Negative  12 (20,7) 9 (45,0)  
0,0383# 
18 (26,1) 3 (27,3)  
0,9999# 
 
 Positive 44 (75,9) 10 (50,0) 47 (68,1) 8 (72,7) 
 Unknown 2 (3,4) 1 (5,0) 4 (5,8) 0 (-) 
PR  
 Negative 31 (53,5) 12 (60,0)  
0,4273# 
35 (50,7) 8 (72,7)  
0,1740#  Positive 25 (43,1) 6 (30,0) 30 (43,5) 2 (18,2) 
 Unknown 2 (3,4) 2 (10,0)  4 (5,8) 1 (9,1) 
Metastasis site       
 Bone only 11 (19,0) 7 (35,0)  
0,0555$ 
15 (21,7) 3 (27,3)  
 Visceral only 32 (55,2) 5 (25,0) 36 (52,2) 7 (63,6) 0,5057$ 
 Bone & Visceral 
Unknown 
14 (24,1) 
1 (1,7) 
8 (40,0) 
 0 (-) 
17 (24,6) 
1 (1,5) 
1 (9,1) 
0 (-) 
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Next, we evaluated the association between YB-1 and p-YB-1 expression and 
clinical outcomes, namely OS and RFS. Kaplan-Meyer analysis shows that patients with 
elevated expression of YB-1 (YB-1High) have decreased OS (p=0,0437; HR=0,538; 95%CI 
0,2525-1,145) (Figure 3.A). There was no association between p-YB-1 and OS 
(p=0,0916; HR=2,321; 95%CI 1,114-4,835) (Figure 3.B); or between YB-1 (p=0,4615; 
HR=0,822; 95%CI 0,473-1,429) and p-YB-1 expression (p=0,2963; HR=1,468; 95%CI 
0,7741-2,785) and RFS (Figure 3.C and D, respectively). 
 
Figure 3. High levels of YB-1 in BC tumours are associated with shorter patient survival. Kaplan-Meier 
Overall Survival (OS) curves according to (A) YB-1 expression (HR=0,538; 95%CI 0,253-1,145) and (B) p-
YB-1 expression (HR=2,321; 95%CI 1,114-4,835); and Relapse-free Survival (RFS) curves according to (C) 
YB-1 expression (HR=0,822; 95%CI 0,473-1,429) and (D) p-YB-1 expression (HR=1,468; 95%CI 0,774-
2,785) in primary BC patients. P-Value and Hazard ratio (HR) was calculated using log-rank test and 
significance set at 0,05. 
 
Since previous studies have shown that oncogenic function of YB-1 is associated 
with protein phosphorylation and nuclear translocation, we also evaluated the cellular 
localization of YB-1 and p-YB-1 (Figure 2.C) and analysed the association between 
nuclear YB-1 or p-YB-1 and the clinical and pathological characteristics referred above 
(Table 6). In this study, 29,5% of patients (24/78) had positive nuclear YB-1 and 36,3% 
(29/80) positive nuclear p-YB-1. Nuclear p-YB-1 was significantly associated with ER 
status (p=0,0306).  
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Table 6. Association between nuclear YB-1 and p-YB-1 expression in primary breast tumours and 
clinicopathologic characteristics.  
 
  #Fisher’s exact test; $Chi-Square test 
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  We then evaluated the association between nuclear YB-1 and p-YB-1 and 
clinical outcomes. Kaplan-Meyer analysis shows that although not significant, OS 
curves tend to segregate patients, being the ones with positive nuclear YB-1 and p-YB-
1 the ones with lower OS (YB-1: p=0,1754; HR=0,675; 95% CI 0,360-1,266; p-YB-1: 
p=0,7525; HR= 0,917; 95% CI 0,524-1,605) (Figure 4.A and B). This trend is more 
evident for patients who died within 5 years of follow-up. Since the median OS in this 
cohort was 4,93 years, we also performed a 5-year survival analysis, which shows that 
in fact nuclear YB-1 and p-YB-1 are markers of shortest OS (YB-1: p=0,0221 HR=0,432; 
95% CI 0,182-1,022; p-YB-1: p=0,0163; HR=0,422; 95% CI 0,1923-0,926) (Figure 4.C and 
D). Concerning RFS, no differences were observed (YB-1: p=0,2594; HR=0,759; 95% CI 
0,450-1,281; p-YB-1: p=0,8934; HR=0,971; 95% CI 0,617-1,529) (Figure 4.E and F). 
 
Figure 4. Positive nuclear YB-1 or p-YB-1 is associated with poor 5-years survival. Kaplan-Meier Overall 
Survival (OS) curves according to (A) YB-1 nuclear staining (HR=0,675; 95% CI 0,360-1,266), (B) p-YB-1 
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nuclear staining (HR= 0,917; 95% CI 0,524-1,605); Kaplan-Meier 5-years Overall Survival (OS) curves 
according to (C) YB-1 nuclear staining (HR=0,432; 95% CI 0,182-1,022), (D) p-YB-1 nuclear staining 
(HR=0,422; 95% CI 0,1923-0,926); and Kaplan-Meier Relapse-free Survival (RFS) curves according to (E) 
YB-1 nuclear staining (HR=0,759; 95% CI 0,450-1,281), (F) p-YB-1 nuclear staining (HR=0,971; 95% CI 
0,617-1,529). P-Value and Hazard ratio (HR) were calculated using log-rank test and significance set at 
0,05. 
 
  
4.2. Prognostic value of YB-1 and p-YB-1 expression in metastatic BC 
Since YB-1 expression is implicated in tumour aggressiveness and progression, 
we also analysed the expression of YB-1 and p-YB-1 in 51 paired metastases. Patients 
were dichotomized as described above and 31,4% (16/51) were classified as YB-1 high 
and 9,8% (5/51) as p-YB-1 high; without association with clinicopathologic 
characteristics (Table 7).  
Table 7. Association between YB-1 and p-YB-1 expression in metastatic tissue and clinicopathologic 
characteristics. 
 
   #Fisher’s exact test. 
 
Characteristics YB-1 (%) p p-YB-1 (%) P 
 Low High  Low High  
Nº of Patients 35 16  46 5  
Age at diagnosis (years)  
  Median 
(range) 
53 
(30 – 82) 
63 
(39 – 77) 
 
 
54 
(30 - 82) 
66 
(45 – 81) 
 
 
Adjuvant HT  
 Yes 21 (60,0) 13 (81,2)  
0,3238#  
 
28 (60,9) 4 (80,0)  
>0,9999 # 
 
 No 12 (34,3) 3 (18,8) 14 (30,4) 1 (20,0) 
 Unknown 2 (5,7) 0 (-) 4 (8,7) 0 (-) 
HER2  
 Negative 23 (65,7) 10 (62,5)  
0,7290 # 
 
31 (67,4) 2 (40,0)  
0,5654 # 
 
 Positive 10 (28,6) 3 (18,75) 11 (23,9) 2 (40,0) 
 Unknown 2 (5,7) 3 (18,75) 4 (8,7) 1 (20,0) 
ER  
 Negative  11 (31,4) 3 (18,8)  
0,4967 # 
 
13 (28,3) 1 (20,0)  
>0,9999 # 
 
 Positive 21 (60,0) 11 (68,7) 29 (63,0) 3 (60,0) 
 Unknown 3 (8,6) 2 (12,5) 4 (8,7) 1 (20,0) 
PR  
 Negative 19 (54,3) 7 (43,7)  
0,9999 # 
 
24 (52,2) 2 (40,0)  
>0,9999 # 
 
 Positive 14 (40,0) 6 (37,5) 18 (39,1) 2 (40,0) 
 Unknown 2 (5,7) 3 (18,8) 4 (8,7)       1 (20,0) 
Metastasis site       
 Bone only 7 (20,0) 3 (18,75)  9 (19,6) 2 (40,0)  
 Visceral only 22 (62,9) 10 (62,5) 0,9876# 28 (60,8) 3 (60,0) 0,3961# 
 Bone & Visceral 6 (17,1) 3 (18,75)  9 (19,6) 0 (-)  
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Concerning the impact of metastatic YB-1 and p-YB-1 in survival after relapse, 
we observed a non-significant tendency toward decreased OS in patients with elevated 
YB-1 (p=0,2955; HR=0,661; 95%CI 0,277-1,577) (Figure 5.A); and no association 
between p-YB-1 and OS (p=0,1276; HR and 95% CI: undefined) (Figure 5. B). In this 
analysis, one patient with missing follow-up data was excluded. 
 
 
Figure 5. High levels of YB-1 in BC metastasis are not associated with shorter patient survival. Kaplan-
Meier Overall Survival (OS) curves according to (A) YB-1 expression (HR=0,661; 95%CI 0,277-1,577) and 
(B) p-YB-1 expression (HR and 95%CI: undefined); P-Value and Hazard ratio (HR) was calculated using 
log-rank test and significance set at 0,05. 
 
 
 
Additionally, we analysed the association of nuclear YB-1 and p-YB-1 expression 
in metastatic tissue, with clinical and pathological characteristics (Table 8). One sample 
in the case of nuclear YB-1 and two samples in the case of nuclear p-YB-1 were 
classified as “undefined” and excluded from analysis. In this cohort, 28% (14/50) of 
patients had positive nuclear YB-1 and 50% (24/48) positive nuclear p-YB-1. Positive 
nuclear YB-1 was associated with adjuvant HT (p=0,0039), and positive nuclear p-YB-1 
with visceral-only recurrence (p=0,0350) (Table 8). 
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Table 8. Association between nuclear YB-1 and p-YB-1 expression in metastatic breast tumours and 
clinicopathologic characteristics. 
 
#Fisher’s exact test. 
 
Moreover, we observed a non-significant tendency to decreased OS in patients 
with positive nuclear p-YB-1 (YB-1: p=0,2824; HR= 0,597; 95%CI 0,258-1,379; p-YB-1: 
p=0,1766; HR= 0,601; 95%CI 0,286-1,262) (Figure 6.A and B).  
 
 
Figure 6. Positive nuclear p-YB-1 in metastasis is not associated with shorter OS. Kaplan-Meier Overall 
Survival (OS) curves according to (A) YB-1 nuclear staining (HR= 0,597; 95%CI 0,258-1,379) and (B) p-YB-
Characteristics YB-1 (%) p p-YB-1 (%) P 
 Positive Negative  Positive Negative  
Nº of Patients 14 36  24 24  
Age at diagnosis (years)  
  Median 
(range) 
60 
(41 – 81) 
54 
(30 – 82) 
 
 
60 
(37 - 82) 
54 
(30 – 78) 
 
 
Adjuvant HT  
 Yes 13 (92,9) 19 (52,8)  
0,0039#  
 
18 (75,0) 13 (54,2)  
0,2078# 
 
 No 0 (-) 15 (41,7) 5 (20,8) 9 (37,5) 
 Unknown 1 (7,1) 2 (5,6) 1 (4,2) 2 (8,3) 
HER2  
 Negative 6 (42,8) 26 (72,2)  
0,4411# 
 
17 (70,9) 14 (58,4)  
0,5098 # 
 
 Positive 4 (28,6) 9 (25,0) 5 (20,8) 8 (33,3) 
 Unknown 4 (28,6) 1 (2,8) 2 (8,3) 2 (8,3) 
ER  
 Negative  3 (21,4) 11 (30,5)  
>0,9999 # 
 
4 (16,7) 10 (41,7)  
0,1040 # 
 
 Positive 7 (50,0) 24 (66,7) 18 (75,0) 12 (50,0) 
 Unknown 4 (28,6) 1 (2,8) 2 (8,3) 2 (8,3) 
PR  
 Negative 5 (35,7) 21 (58,3)  
0,4851# 
 
11 (45,8) 13 (54,2)  
0,3815 # 
 
 Positive 6 (42,9) 13 (36,1) 12 (50,0) 8 (33,3) 
 Unknown 3 (21,4) 2 (5,6) 1 (4,2)       3 (12,5) 
Metastasis site       
 Bone only 2 (14,3) 8 (22,2)  1 (4,2) 8 (33,3)  
 Visceral only 10 (71,4) 21 (58,3) 0,6889# 16 (66,7) 11 (45,8) 0,0350# 
 Bone & Visceral 2 (14,3) 7 (19,5)  7 (29,1) 5 (20,8)  
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1 nuclear staining (HR= 0,601; 95%CI 0,286-1,262); P-Value and Hazard ratio (HR) was calculated using 
log-rank test and significance set at 0,05. 
 
  
Next, we compared the expression of YB-1 and p-YB-1 in primary tumours and 
metastases. Median YB-1 H-Score was similar (p=0,3560) (Figure 7.A), while the levels 
of p-YB-1 were significantly reduced in metastases (p=0,0345) (Figure 7.B). In this 
cohort, 7 out of 12 patients with elevated p-YB-1 in primary tumour had a decrease in 
p-YB-1 expression in the metastasis sample. So, we questioned if the loss in p-YB-1 
expression in metastases could be associated with the technical processing of samples 
affecting IHC. Sample processing may differ according to the specific metastatic tissue, 
for example, including sample decalcification in the case of bone metastases. However, 
there was no difference between metastases location in terms of median H-scores 
when comparing bone and non-bone metastases (Figure 7.C and D).  
 
 
 
Figure 7. Box plot graphics of (A) YB-1 and (B) p-YB-1 H-score in primary tumours and paired 
metastases (n=51); and (C) YB-1 and (D) p-YB-1 H-score in bone or non-bone metastases. P-value was 
calculated using unpaired t-test and * p<0,05. 
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The analysis of the cohort of paired primary tumours and metastasis showed a 
switch in the molecular status from the primary to the metastatic tumour in 20 cases 
out of 51. To answer the question if YB-1 expression was associated with this switch, 
namely with ER and/or PR loss and HER2 gain, we looked for molecular receptors’ 
alterations in cases with high YB-1 expression in the primary tumour (14/51) or 
metastasis (16/51), in comparison with cases with low YB-1 expression (Figure 8). Gain 
in HER2 (four cases) and loss of ER (five cases) were equally balanced between the 
groups; whereas loss of PR (eight cases) was predominant in cases with low YB-1 
expression (7/8; 87,5%). The nuclear staining was also evaluated, and it was not 
associated with total YB-1 expression or alteration in molecular receptors’ status.  In 
this case, there were 24 positive cases for nuclear YB-1 and one correspond with a case 
of loss of HER2, two tumours corresponds to loss of ER and four with the loss of PR. 
 
 
 
Figure 8. Schematic representation of YB-1, p-YB-1 expression and nuclear YB-1 in primary tumours 
and HER2, ER and PR clinical status in primary and metastatic tumours. 
 
After, we extended the analysis for our entire cohort of primary tumours 
(n=78), where 20/78 were YB-1High and 58/78 were YB-1Low. The distribution of YB-1 
expression, nuclear localization, HER2 expression and Hormone Receptors expression 
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are represented in Figure 9. The number of these cases remained balanced between 
tumours with low or high expression of YB-1; with 8/20 YB-1High cases (40,0%) and 
24/58 YB-1Low (41,4%) cases presenting at least one alteration. HER2 alterations 
occurred in 8 metastases, ER alteration in 11 metastases, and PR alterations occurred 
in 20 metastases. However, molecular alterations were more frequent in metastases 
from YB-1Nuc+ primary tumours (11/24; 45,8%) than in metastases from YB1Nuc- primary 
tumours (20/54; 37%).  
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Figure 9. Schematic representation of YB-1 expression and YB-1 nuclear staining in primary tumours 
and HER2, ER and PR clinical status in primary and metastatic tumours. Cases were ordered from the 
weakest (up) to the strongest staining (down) of total YB-1. 
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4.3. YB-1 expression and resistance to therapy in BC cell lines 
4.3.1. Impact of YB-1 overexpression in sensitivity to therapy 
To answer our question if YB-1 expression is affected by exposure to HT and/or 
related to acquired resistance, we used a panel of four Luminal BC cell lines (ER+HER2-: 
MCF-7 and T47D; ER+HER2+: BT474 and MDA-361). From herein, MDA-MB-361 cell 
line is designated by MDA-361. These cells express similar levels of YB-1 but less than 
the TNBC cell line MDA-MB-231 as expected (Figure 10). We also confirmed the 
expression of ERBB2, ESR1, PGR and CCND1, as well as the protein levels of YB-1, ER 
and HER2 in these cells, which was in accordance with their molecular subtype.  
 
Figure 10. YBX1, ERBB2, ESR1, PGR and CCND1 mRNA and protein levels in a panel of BC cell lines. (A) 
Relative mRNA expression was quantified by RT-qPCR and normalized to GAPDH gene. The experiments 
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were done in triplicate (except PGR and CCND1) and results presented as the meanSEM. (B) YB-1, ERα 
and HER2 protein expression was evaluated by Western Blot, using β-actin as loading control.  
 
Next, we selected the MCF-7 cell line to overexpress YB-1 by lentiviral 
transduction. YB-1 overexpression (OE) was confirmed by RT-qPCR (Figure 11.A) and 
Western Blot (Figure 11.B). We obtained a 3-fold increase in YB-1 mRNA; and 1,55-fold 
and 1,63-fold increase in YB-1 total and phosphorylated protein levels, respectively. 
We also characterized the expression of Hormone Receptors (ER and PR), HER2, and 
the ER-downstream target gene CCND1 (cyclin D1) in YB-1 OE cells (herein designated 
MCF-7YB-1 OE), by RT-qPCR and/or Western blot (Figure 11.A and 11.B, respectively). 
MCF-7YB-1 OE cells have decreased expression of ER, without significant decrease in 
CCND1 expression. In accordance, we did not observe a difference in proliferation rate 
of MCF-7YB-1 OE cells when comparing to parental MCF-7 cells (Figure 11.C). 
Figure 11. YB-1 overexpression in MCF-7 cell line decreases ER expression. (A) Relative mRNA 
expression was quantified by RT-qPCR and normalized to GAPDH gene. Gene fold change was 
determined using the 2-ΔΔCt method. p-value was calculated using unpaired t-test and significance set 
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at 0,05. (YBX1: p=0,0099; ERBB2: p=0,1641; ESR1: p<0,0001; PGR:p=0,2432) (B) Protein expression was 
evaluated by Western Blot and β-Actin was used as loading control. (C) Proliferation was assessed by 
Alamar blue viability assay. Experiments were performed in triplicate, and results presented as the 
meanSEM. p-value was calculated using two-way ANOVA and significance set at 0,05. 
 
 
We later assessed the effect of YB-1 OE over MCF-7 sensitivity to five different 
drugs, used to treat Luminal BC, namely the HT drugs tamoxifen and fulvestrant; the 
anti-HER2 lapatinib, since we observe a slight increase in ERBB2 mRNA expression; the 
mTOR inhibitor everolimus; and the CDK4/6 inhibitor palbociclib. Cells were exposed 
to different drugs’ concentrations for seven days, after which cell viability was 
measured by Alamar blue assay (Figure 12). MCF-7YB-1 OE cells were less sensitive to HT 
(tamoxifen: p=0,0192; fulvestrant: p=0,0433); and more sensitive to lapatinib 
(p=0,0065), whereas no differences were observed concerning everolimus and 
palbociclib. 
 
Figure 12. Overexpression of YB-1 decreases sensitivity to HT but sensitizes cells to anti-HER2 
lapatinib. Cells were seeded in 96-well plates and exposed to different drugs for seven days. Medium 
was replaced every two days, and viability was assessed by Alamar blue assay. Results are the mean of 
three independent assays, with 4 replicates per assay, and presented as the meanSEM. p-value was 
calculated using paired t-test, *p<0,05 and **p<0,01. Hormone therapy: Tamoxifen (p=0,0192) and 
Fulvestrant (p=0,0433); Anti-HER2: Lapatinib (p=0,0065); mTOR inhibitor: Everolimus; CDK4/6 inhibitor: 
Palbociclib.    
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Together, these data show that YB-1 expression is implicated in the modulation 
of important receptors, like HER2 and ER, and affects cell responsiveness to therapy. 
Therefore, we further aimed to test if under therapy, YB-1 overexpressing cells are 
selected and implicated in acquired resistance. 
 
4.3.2. Modulation of YB-1 expression and sensitivity profiles after long-
term exposure to low-dose therapies 
 
Next, to select resistant clones, cells were exposed for five months to low doses 
of the different drugs. The best dose, that killed approximately 50% of cells, was 
chosen after assessing the sensitivity of each cell line to the different drugs to be 
tested (Figure 13).  
 
 
Figure 13. Baseline sensitivity profiles assessed by Alamar blue viability assay. Cells were seeded in 96-
well plates and exposed to different drugs for seven days. Results are the mean of three independent 
assays, with four replicates per assay, and presented as the meanSEM. Hormone therapy: Tamoxifen 
and Fulvestrant; Anti-HER2: Lapatinib; mTOR inhibitor: Everolimus; CDK4/6 inhibitor: Palbociclib.    
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Based on these results, the four parental cell lines were exposed to a fixed 
concentration of 10nM tamoxifen (TAM), 10nM fulvestrant (FULV), 100nM lapatinib 
(LAP), 100nM everolimus (EVE) and 10nM of palbociclib (PALB) for five months. During 
this period, a first evaluation of the sensitivity profiles was performed after 3 months. 
When comparing untreated with treated cells, designated as “_R” cells, we found 
there was not a significant difference (Figure 14). Missing combinations are due to 
difficulty in maintaining some cells in culture, for different technical reasons, including 
MDA-361 cells exposed to fulvestrant or everolimus, or BT474 exposed to everolimus 
and palbociclib. 
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Figure 14. Sensitivity profiles after 3 months of drug’s exposure assessed by Alamar blue viability 
assay. Cells were seeded in 96-well plates and exposed to different drugs for seven days. Results are the 
mean of four replicates of one assay and presented as the meanSEM. p-value was calculated using 
paired t-test and *p<0,05. Hormone therapy: Tamoxifen and Fulvestrant; Anti-HER2: Lapatinib; mTOR 
inhibitor: Everolimus; CDK4/6 inhibitor: Palbociclib 
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Based on this interim evaluation, we continued the experiment with MCF-7 and 
T47D cells, exposed to tamoxifen and fulvestrant; and the four cell lines exposed to 
lapatinib. After five months of continuous exposure to these drugs we re-assessed the 
sensitivity profiles to each drug. All treated cells were less sensitive to drugs, in 
comparison to the respective parental cells (untreated), although MCF-7 cells exposed 
to fulvestrant and T47D cells exposed to lapatinib did not reached a statistically 
significant difference (Figure 15).  
 
 
 
Figure 15. Sensitivity profiles after 5 months of drug’s exposure assessed by Alamar blue viability 
assay. (A) Tamoxifen; (B) Fulvestrant; (C) Lapatinib. Viability Assays was measured by Alamar Blue assay 
after 7 days of exposure to drugs. The experiments were done with four replicates per assay and 
presented as the meanSEM. p-values were calculated using paired t-test and *p<0,05.  
 
Next, we assessed whether YB-1, ER, HER2, PR and cyclin D1 were differentially 
expressed in resistant cells (time of exposure t=5 months) in comparison to parental 
ones (t=0), by RT-qPCR and Western blot. In cells resistant to tamoxifen we observed a 
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decrease in hormone receptors expression (ER and PR) in MCF-7 cells, but an increase 
in T47D cells (Figure 16.A and Figure 17).  Upon exposure to fulvestrant, T47D cells 
show an increase in ERBB2 expression which did not translated into increased amount 
of protein (Figure 16.B and Figure 17), and both Luminal A cell lines had a major down-
regulation of PGR (Figure 16.B). Regarding lapatinib treated cells (Figure 16.C), it was 
observed an up-regulation in all genes in T47D cells, a down-regulation in hormone 
receptors in MCF-7 cells, and increased YB-1 expression in T47D and MDA-361 cells. At 
the protein level, we confirmed the up-regulation of YB-1 and ER in T47D cells resistant 
to tamoxifen and fulvestrant, and the down-regulation of ER in MCF-7 cells resistant to 
tamoxifen and fulvestrant; but not the increase in YB-1 in T47D and MDA-361 cells 
resistant to lapatinib (Figure 17). Expression of cyclin D1 followed the differential 
expression of its major regulator ER. 
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Figure 16. YBX1, ERBB2, ESR1 and PGR expression levels in cells resistant to (A) tamoxifen (B) fulvestrant and (C) 
lapatinib.  mRNA of gene expression was quantified by RT-qPCR and normalized to 18S gene. Gene fold 
change was determined using the 2-ΔΔCt method and expression was normalized to untreated parental 
cells (0). The experiment was done in triplicate and results presented as the meanSEM.  
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Figure 17. Protein expression in tamoxifen, fulvestrant, and lapatinib resistant cells. p-YB-1, YB-1, 
HER2, ER and CyclinD1 protein expression was evaluated by Western Blot and β-Actin was used as 
loading control. 
 
Since YB-1, ER and Cyclin D1 are associated with proliferation, we also assessed 
the proliferation rate of resistant cells in comparison to untreated parental cell lines. In 
general, proliferation was not significantly affected in resistant cells (Figure 18.A).  
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Figure 18. Proliferation rates in cells resistant to (A) Tamoxifen; (B) Fulvestrant; and (C) Lapatinib. 
Proliferation was measured by Alamar Blue assay for 3 days. The experiments were done with four 
replicates and results presented as the mean SEM. p-value were calculated using paired t-test and 
significance set as 0,05.. 
 
 
Since the proliferation of ER+ cells is estradiol-dependent, we questioned if the 
lower expression of ER in MCF-7 TAM_R and FULV_R cells (Figure 17) could be 
associated with the lower proliferation rate. Therefore, we assessed the sensitivity to 
17β-estradiol of MCF-7 TAM_R cells in comparison with MCF-7 parental cells. MCF-7 
TAM_R cells were less sensitive to 17β-estradiol depletion, although still sensitive to β-
estradiol addition (Figure 19).  
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Figure 19. Estradiol sensitivity assay. After β-estradiol complete depletion from culture medium, cells 
were cultured in the presence of 0nM, 1nM or 10nM β-estradiol for 5 days. Viable cells were measured 
by Alamar Blue Assay. *p<0,05, **p<0,01 ***p<0,001 and p-value were calculated using One-way 
ANOVA. 
 
 
3.3.3. Sensitivity profile of tamoxifen and fulvestrant resistant cells to 
alternative therapeutic options 
Since Luminal A cells resistant to tamoxifen and fulvestrant were found to have 
molecular alterations in YB-1, ER, HER2 and/or cyclin D1, we chose to evaluate the 
response of those cells to alternative therapies like lapatinib, everolimus and 
palbociclib.  MCF-7 cells resistant to fulvestrant were more sensitive to everolimus and 
to palbociclib; and there was also a trend for sensitivity to palbociclib in T47D cells 
resistant to fulvestrant (Figure 20).  
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Figure 20. Sensitivity profiles assessed by Alamar blue viability to (A) anti-HER2, (B) mTOR inhibitor 
and (C) CDK4/6 inhibitor. Viability Assays was measured by Alamar Blue assay after 7 days of exposure 
to drugs. Cells were seeded in 96-well plates and exposed to drugs for seven days. Results are the mean 
of four replicates and presented as the meanSEM. p-value were calculated using paired t-test and 
significance set at 0,05. 
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5. DISCUSSION 
 
BC is the most diagnosed cancer among women worldwide, and Luminal BC is 
the most frequent subtype corresponding to 60% of new cases per year.1 Despite 
significant therapeutic improvements in recent years, about 30% of women will 
develop metastatic BC.4 Since resistance to therapy will dictate the success of 
metastatic care, it is extremely important to address resistance mechanisms and to 
find reliable predictive biomarkers. 
YB-1 affects the expression of a variety of genes related with oncogenic 
signalling pathways45,56,61 and was recently described as a transcriptional modulator of 
ER and HER2 expression, involved in resistance to HT.63 Therefore, we were interested 
in study its role as a possible prognostic and predictive biomarker in Luminal BC. 
Different studies have shown that high levels of YB-1 are associated with poor 
prognosis60,61 especially when YB-1 is located in the nucleus. In this way, we started by 
analysing the impact of YB-1 and p-YB-1 in RFS and OS in a cohort of 80 BC patients. In 
this cohort, and in line with other reported analyses43,66, elevated YB-1 was associated 
with a negative ER status; and there was also a trend for association between low YB-1 
and visceral-only metastasis (Table 5). Accordingly, and also as previously described60, 
elevated YB-1 was a biomarker of worst clinical outcome, translated into decreased OS 
(Figure 3.A).  Although some studies have related the levels of YB-1 with metastasis 
development60, in this cohort there was no association with RFS (Figure 3.C and D). To 
our knowledge this was the first study of p-YB-1 as a prognostic biomarker. We did not 
find any association with clinicopathologic characteristics or clinical outcome. 
YB-1 regulates different cellular functions accordingly to its cellular location. 
Once activated by phosphorylation, cytoplasmic YB-1 translocates to the nucleus 
where it acts as transcription factor.34 So, we looked for associations between nuclear 
YB-1 and p-YB-1 and clinicopathological characteristics. In this cohort, there was an 
association between nuclear p-YB-1 and negativity of ER (Table 6). Then, we assessed 
the impact of nuclear YB-1 or p-YB-1 in OS and RFS, and both YB-1 and p-YB-1 positive 
nuclear staining showed a trend towards decreased OS, particularly in the first years of 
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follow-up (Figure 4.A and B). As the median OS of this cohort was 4,93 years, we 
performed a 5-year survival analysis, showing that nuclear YB-1 and p-YB-1 are 
biomarkers of decreased 5-years OS (Figure 4.C and D).  
 We also analysed a cohort of 51 paired metastases. No association between YB-
1 or p-YB-1 and clinical characteristics was found (Table 7). However, elevated YB-1 
was again a biomarker of worst OS (Figure 5.A). Concerning p-YB-1 there were no 
differences between the two arms, but it should be noted that there were only five 
patients in the YB-1High arm and all of them were alive in the last follow-up (Figure 5.B). 
Putting primary tumours aside, we next assessed the impact of nuclear YB-1 and p-YB-
1 in this cohort of metastases. We found an association between nuclear YB-1 and 
adjuvant HT; and between nuclear p-YB-1 and visceral metastasis (Table 8). This 
suggests that adjuvant HT may drive the selection of clones with elevated YB-1 
expression. Concerning clinical outcomes, there was no association between nuclear 
YB-1 or p-YB-1 with OS after relapse (Figure 6). 
 We observed that p-YB-1High cases were a minority, and to discard the 
hypothesis that this was influenced by technical processing of samples, as 
decalcification of bone metastases, we assessed the levels of YB-1 and p-YB-1 in bone 
versus non-bone metastasis, which were similar (Figure 7). 
It is known that the expression of HER2, ER and PR can change from primary 
tumours to metastasis. Since YB-1 has been described as a regulator of ER and HER2 
expression in vitro, we performed the first analysis of association between YB-1 
expression and HER2, ER and PR status in the clinical setting. We identified the cases 
with alteration in molecular status of HER2, ER and/or PR, but in our cohort, there was 
no obvious association with YB-1 or p-YB-1 expression. Nevertheless, all cases with 
alteration and YB-1High corresponded to loss of ER/PR and gain of HER2 (Figure 8 and 
Figure 9).  It is important to validate these results in a larger cohort.  
Overall, our analysis in a cohort of 80 primary BC tumours and 51 paired 
metastases corroborates the importance of YB-1 as a biomarker of poor prognosis and 
shows that it is implicated in ER negativity and HER2 positivity. Moreover, we provide 
the first data that shows that adjuvant HT may be implicated in the selection of clones 
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with elevated YB-1 expression and this may be associated with the poor outcome of 
YB-1High patients.  
Therefore, we proposed to understand if and how YB-1 expression is associated 
with acquired resistance to HT. We used an in vitro model, with a panel of four Luminal 
BC cell lines (ER+HER2-: MCF-7 and T47D; ER+HER2+: BT474 and MDA-361) (Figure 10). 
As mentioned before, YB-1 upregulation has been previously associated with 
decreased ER and increased HER2 expression, in ER+ BC cells T47D.63 Accordingly, our 
results showed that YB-1 overexpression in MCF-7 cells led to a slight increase in 
ERBB2 and a significant decrease in ESR1 (Figure 11.A and B). The expression of PGR 
was not affected by upregulation of YB-1. Since ESR1 and CCND1 were decreased, we 
also asked whether proliferation would be influenced. However, no effect on 
proliferation was observed (Figure 11.C).  
As expected upon the decrease in ER, cells overexpressing YB-1 show intrinsic 
decreased sensitivity to tamoxifen and fulvestrant; furthermore, MCF-7YB-1 OE was more 
responsive to the anti-HER2 Lapatinib (Figure 12). Lapatinib is a tyrosine kinase 
inhibitor that inactivates HER2 signalling pathway. Therefore, an increase in HER2 
expression is predictive of better response.  
We also hypothesised that YB-1 could be associated with acquired resistance to 
HT. It has already been demonstrated that T47D Luminal BC cells treated with two HT 
drugs have high level of YBX1 expression.63 Thus, we exposed the four cell lines MCF-7, 
T47D, MDA-361 and BT474 to a low concentration of tamoxifen, fulvestrant, lapatinib, 
everolimus and palbociclib for five months, to select the resistant ones (Figure 13). The 
drugs were chosen based on clinical relevance. Tamoxifen and fulvestrant are standard 
of care therapies for ER+ BC; and Lapatinib, Everolimus and Palbociclib are second line 
treatments for metastatic BC.  
There are three molecular targets particularly relevant for the treatment of metastatic 
Luminal BC. In the case of HER2 overexpression67, the use of the anti-HER2 tyrosine kinase 
inhibitor lapatinib has shown efficacy in combination with HT15. PI3K/AKT/mTOR pathway is in 
most cases mutated and constitutively hyperactivated21,55; and some studies have shown that 
patients who have decontrolled mTOR pathway benefit from mTOR inhibitors, like 
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everolimus.22,23 Finally, CDK4/6 inhibitors have been identified as a good option to treat 
metastatic ER+HER2- BC, in combination with HT.33 
An interim three months evaluation of sensitivity (Figure 14), and technical 
aspects related to culture maintenance dictated that MCF-7 and T47D cells, cultured in 
the presence of tamoxifen, fulvestrant and lapatinib; and BT474 and MDA-361 cells 
cultured in the presence of lapatinib were used for the final 5 months analysis (Figure 
15). All cell lines exhibited decreased sensitivity to the respective selection drugs. 
After that, we evaluated the expression of YB-1 and analysed if it was 
associated with differential expressions of ER, PR and HER2, as it has been reported 
before.60,63 PR is a hormone receptor activated by progesterone and it is often 
expressed in Luminal BC and, as ER, promotes cell development and proliferation.68 
Also, it has been associated in a negative manner with the expression of YB-1.34 
Although we did not observe a significative difference in the expression of YB-1 or 
HER2 in MCF-7 cells resistant to HT, ER and PR decreased. However, T47D cells 
exposed to HT showed an increase in YB-1, HER2 and ER (Figure. 16 and Figure. 17). 
We also observed an increase in YB-1, ERBB2, ESR1 and PGR in T47D cells resistant to 
lapatinib, but downregulation of ER and PR in lapatinib resistant-MCF-7 cells. Further 
studies should be done to clarify both the results obtained in this analysis and the 
impact of YB-1 in receptors’ expression. However, in cells with acquired resistance to 
therapy, YB-1 probably does not affect exclusively ER and HER2 expression. A study has 
shown that high expression of YB-1 in BC is accompanied by hyper activation of KRAS, 
inducing the activation of HIF1α, associated with poor prognosis.72 
Additionally, MCF-7 resistant to HT had a lower proliferation rate than parental 
cells (Figure 18). Since these cells, which are estradiol dependent69,70, had decreased 
ER expression and a lower proliferation rate, we measured cell proliferation in the 
absence or presence of 17β-Estradiol (E2). Our data shows that proliferation of 
parental MCF-7 cells was decreased in the absence of E2 and that cells are responsive 
to E2, increasing the proliferation rate. However, HT-resistant MCF-7 cells were not so 
dependent on E2 (Figure 19), which can suggest that, although they also rely on the 
activation of ER-pathway, other pathways will compensate the decrease in ER 
expression and subsequent signalling.  
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Metastatic BC is a challenge for clinicians and researchers and until now many 
mechanisms have been discovered and targeted to treat patients. An in vitro study has 
previously demonstrated that anti-HER2 therapies could be an alternative treatment 
for HT-resistant Luminal A BC (HER2-) with YB-1 overexpression.63 In the same line, we 
tested the sensitivity of MCF-7 and T47D HT-resistant cells to lapatinib. MCF-7 
resistant to fulvestrant are a quite more sensitivity to lapatinib. Moreover, we also 
tested the sensitivity of these cells to everolimus and palbociclib. In general, although 
not statistically significative, HT-resistant clones have a trend to be more sensitive to 
alternative drugs (Figure 20).  
   
 
YB-1 expression in breast cancer: modulation of receptor status and therapeutic implications 
 
 
47 
 
6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
YB-1 overexpression has been described as an oncogenic driver and marker, 
associated with drug resistance and poor clinical outcome in BC. As a negative ER 
modulator, YB-1 is mainly expressed in TNBC. Also, among BC, YB-1 expression has 
been related with decreased OS. Accordingly, in our cohort we demonstrated that high 
expression of YB-1, as well as nuclear YB-1, were associated with negative ER 
molecular status and with decreased OS.  Interestingly, metastases from patients who 
benefited from adjuvant HT were enriched in elevated YB-1 expression. 
Our in vitro study, using MCF-7 cells for the first time, corroborates that 
increasing YB-1 in Luminal BC results in the downregulation of ESR1, and less available 
ER in cells. This alteration is most likely responsible for the observed resistance to HT, 
tamoxifen and fulvestrant. On the other hand, cells which have been exposed to HT 
and anti-HER2 drugs, showed differences in the expression of receptors ER, PR and 
HER2; however, we did not see significant differences on the levels of YB-1.  
Importantly, we also have demonstrated that HT-resistant cells remained sensitive to 
alternative therapies such as lapatinib, everolimus and palbociclib, that are used in 
clinical practice for metastatic BC. 
All results considered, our findings are important for future YB-1 studies in the 
context of BC, as we suggest that overexpressed YB-1 and its nuclear localization can 
be predictive biomarkers for HT resistance. 
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8. SUPPLEMENTARY DATA 
 
Table S 1. Population characteristics of BC samples  
 
 
Characteristics  
 Cohort 
Nº of Patients 80 
Age at diagnosis (years)  
  Median 
(range) 
52 
Menopausal Status (n, %)  
 Premenopausal 29 
 Postmenopausal 46 
 Unknown 5 
TNM Stage  
 I 5 
 II 19 
 III 22 
 IV 14 
 Unknown 20 
T  
 1 22 
 2 27 
 3 4 
 4 9 
 Unknwon 18 
N   
 0 20 
 1 13 
 2 9 
 3 10 
 Unknown 28 
Tumor Grade  
 1 1 
 2 38 
 3 26 
 Unknown 15 
HER2  
 Negative 45 
 Positive 24 
 Unknown 11 
ER  
 Negative  21 
 Positive 54 
 Unknown 5 
PR  
 Negative 43 
 Positive 32 
 Unknown 5 
Metastasis site  
 Bone only 18 
 Visceral only 43 
 Bone & Visceral 
Unknown 
18 
1 
 
